B. Riley Issues Positive Outlook for MDGL Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - B. Riley lifted their Q1 2025 earnings per share (EPS) estimates for Madrigal Pharmaceuticals in a research note issued to investors on Thursday, February 27th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings of ($2.71) per share for the quarter, up from their previous estimate of ($3.34). B. Riley has a "Strong-Buy" rating and a $422.00 price objective on the stock. The consensus estimate for Madrigal Pharmaceuticals' current full-year earnings is ($23.47) per share. B. Riley also issued estimates for Madrigal Pharmaceuticals' Q2 2025 earnings at ($1.83) EPS, Q3 2025 earnings at ($1.20) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($6.02) EPS, FY2026 earnings at $9.82 EPS and FY2027 earnings at $16.60 EPS.

Several other analysts also recently issued reports on the stock. Cantor Fitzgerald reissued a "neutral" rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, November 20th. Citigroup lifted their price target on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. JMP Securities reissued a "market outperform" rating and issued a $427.00 price target on shares of Madrigal Pharmaceuticals in a research report on Friday, January 10th. Finally, HC Wainwright lifted their price target on shares of Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $375.75.

Remove Ads

Madrigal Pharmaceuticals Trading Down 5.3 %

Shares of NASDAQ:MDGL traded down $18.51 during mid-day trading on Monday, hitting $328.77. The company had a trading volume of 344,823 shares, compared to its average volume of 441,473. The firm has a fifty day moving average price of $324.17 and a 200 day moving average price of $287.02. The company has a market capitalization of $7.26 billion, a PE ratio of -13.11 and a beta of -0.38. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93. Madrigal Pharmaceuticals has a one year low of $189.00 and a one year high of $377.46.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) earnings per share for the quarter, beating the consensus estimate of ($4.32) by $1.61. The company had revenue of $103.32 million during the quarter, compared to the consensus estimate of $97.81 million.

Insider Activity at Madrigal Pharmaceuticals

In related news, VP Robert E. Waltermire sold 103 shares of the business's stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $335.24, for a total value of $34,529.72. Following the sale, the vice president now directly owns 4,955 shares in the company, valued at approximately $1,661,114.20. The trade was a 2.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director James M. Daly sold 15,470 shares of the business's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $347.45, for a total value of $5,375,051.50. Following the completion of the sale, the director now owns 1,912 shares in the company, valued at $664,324.40. This represents a 89.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 21,787 shares of company stock worth $7,351,029. Company insiders own 22.80% of the company's stock.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Creative Planning increased its position in shares of Madrigal Pharmaceuticals by 2.7% during the third quarter. Creative Planning now owns 3,299 shares of the biopharmaceutical company's stock valued at $700,000 after buying an additional 87 shares during the period. Nisa Investment Advisors LLC increased its position in shares of Madrigal Pharmaceuticals by 47.6% during the third quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 68 shares during the period. Verity Asset Management Inc. increased its position in shares of Madrigal Pharmaceuticals by 7.4% during the third quarter. Verity Asset Management Inc. now owns 1,466 shares of the biopharmaceutical company's stock valued at $311,000 after buying an additional 101 shares during the period. Assetmark Inc. increased its position in shares of Madrigal Pharmaceuticals by 8.3% during the third quarter. Assetmark Inc. now owns 3,942 shares of the biopharmaceutical company's stock valued at $837,000 after buying an additional 303 shares during the period. Finally, Victory Capital Management Inc. increased its position in shares of Madrigal Pharmaceuticals by 1.8% during the third quarter. Victory Capital Management Inc. now owns 2,292 shares of the biopharmaceutical company's stock valued at $486,000 after buying an additional 40 shares during the period. 98.50% of the stock is currently owned by institutional investors.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.